Abstract library

5 results for "Maurer".
#739 Aspirin Inhibits Cell Viability and mTOR Signalling in Neuroendocrine Tumor Cells
Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as thymic and bronchus carcinoids. Aspirin has been reported to inhibit mTOR signalling and exhibit antitumoral activity in colorectal cancer cells. So far, no data with aspirin on NETs have been published.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Matilde P Spampatti
Authors:
#743 In Vitro Anticancer Effect of Metformin on Neuroendocrine Tumor Cells
Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as bronchus carcinoids. No prophylactic drug is available yet. Metformin has been reported to act on the AMPK/mTOR signalling pathway and exhibit antitumoral activity in several cancer cell lines.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: George Vlotides
Authors:
#874 The pan-TRK Inhibitor GNF5837 Inhibits Cell Viability and Akt and MAPK Signaling in Human Neuroendocrine GOT1 Tumor Cells
Introduction: The tropomyosin receptor kinase family (TRKA, TRKB, TRKC) effects tumor cell growth in various models. Recent preclinical studies in neuroendocrine carcinoma of the lung cell lines have shown that Trk receptors might be a therapeutic target for neuroendocrine neoplasias.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Christoph Auernhammer
Authors:
#1891 GSK3: A Novel Therapeutic Target in NETs?
Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Svenja Nölting
Authors:
#2192 Immunohistochemical Profiles in 81 Patients with Resected Insulinomas
Introduction: Ninety percent of insulinomas are benign. However, there are no well-defined immunohistochemical criteria that can distinguish a benign from a malignant insulinoma
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Mikkel Andreassen
Authors: